GLP-1 Medications and Type 2 Diabetes: How They Lower Blood Sugar

Ozempic and Mounjaro were not invented for weight loss — they were designed for type 2 diabetes. The weight-loss effect was the surprise upside that turned them into household names. Here is how they work in diabetes, and what diabetic patients should know.

Three mechanisms for blood sugar control

GLP-1 medications lower blood glucose through three distinct mechanisms:

1. Suppressing glucagon. Glucagon is the hormone that tells your liver to dump glucose into your bloodstream. In type 2 diabetes, glucagon is inappropriately elevated — your liver is essentially adding fuel to a bonfire. GLP-1s suppress this.

2. Enhancing insulin response. When you eat carbohydrate, GLP-1s amplify your pancreas's insulin release. Critically, this is glucose-dependent — they only ramp up insulin when blood sugar is actually high. This is why hypoglycemia is rare on GLP-1 monotherapy.

3. Slowing gastric emptying. Carbs that arrive at the small intestine slowly produce a smaller, gentler glucose spike. This flattens post-meal blood sugar curves.

What HbA1c reduction to expect

In the SUSTAIN and SURPASS trials, HbA1c reductions averaged:

Semaglutide 1.0 mg: ~1.4% reduction
Semaglutide 2.0 mg: ~1.7% reduction
Tirzepatide 5 mg: ~1.9% reduction
Tirzepatide 15 mg: ~2.1% reduction

For comparison, metformin produces ~1.0% reduction; older sulfonylureas ~1.0–1.5%; insulin can produce more but with hypoglycemia risk.

A patient starting at HbA1c 9.0% can reasonably expect to land in the 6.5–7.5% range on tirzepatide, depending on dose and adherence.

Hypoglycemia risk

GLP-1 monotherapy almost never causes hypoglycemia. The combination is what matters:

GLP-1 + metformin: very low hypoglycemia risk
GLP-1 + DPP-4 inhibitor: low risk
GLP-1 + SGLT2 inhibitor: low risk
GLP-1 + sulfonylurea: moderate-high risk; sulfonylurea dose usually reduced
GLP-1 + insulin: high risk; insulin dose usually reduced 20–50% at start

If you're starting a GLP-1 on insulin or a sulfonylurea, your prescriber should be reducing the other drug, not just adding the GLP-1.

What changes when you also lose weight

Weight loss compounds the blood sugar benefit. Adipose tissue (especially visceral fat) drives insulin resistance. Lose 15% of body weight and your insulin sensitivity improves dramatically — independent of the drug.

Many type 2 diabetics on GLP-1 see their HbA1c normalize as their weight drops, sometimes to the point where they meet criteria for "diabetes remission" (HbA1c below 6.5% off all medications). This is real and well-documented in the DiRECT trial framework. It usually requires 15%+ sustained weight loss.

Cardiovascular benefit beyond glucose

GLP-1s have shown cardiovascular benefit in diabetic patients independent of their glucose effect:

Reduced major adverse cardiovascular events (MACE)
Reduced cardiovascular death
Reduced kidney disease progression in patients with chronic kidney disease

This is why current diabetes guidelines often recommend GLP-1s as first-line therapy alongside or after metformin in patients with cardiovascular risk.

What to monitor

If you're a diabetic on a GLP-1:

HbA1c every 3 months initially, then every 6 months once stable
Glucose patterns if you have a CGM — pay attention to fasting glucose, post-meal spikes, and overnight drift
Kidney function annually
Eye exam annually (rapid HbA1c reduction can transiently worsen retinopathy)
Insulin or sulfonylurea doses — these usually need to come down

Bottom line

GLP-1 medications are powerful blood-sugar drugs. Most diabetic patients see HbA1c reductions of 1.5–2.0 points, with low hypoglycemia risk on monotherapy. Adding weight loss compounds the benefit and can produce remission in some patients. If you're on insulin or sulfonylureas, the dose almost always needs to be reduced when starting a GLP-1 — talk to your prescriber before assuming you can just add it.